Navigation Links
Pharmos Corporation Reports 2009 Second Quarter Results
Date:8/12/2009

n various other areas. The decrease in these costs reflect the closing of the Rehovot facility effective October 31, 2008 and the fact that the Dextofisopam trial is nearing completion.

In the first half of 2009, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial was fully enrolled on April 9, 2009 at 324 patients. Costs of $2,975,000 were incurred during the first half in connection with the trial, comprising CRO-related activities and patient recruitment costs. All patients in the trial completed treatment in July of 2009 and top line clinical data is expected in September 2009. If the trial is successful, the proceeds from the April 2009 financing will support additional efforts to negotiate a partnership or license arrangement with a pharmaceutical company. This is consistent with the Company's strategy as previously communicated, as the Company's plan is to seek a pharmaceutical company as a partner for further development of Dextofisopam.

In process research and development costs which were related to the Vela milestone increased by $1,180,000 from $0 in 2008 to $1,180,000 in 2009. On April 9, 2009 the last patients were enrolled in the Phase 2b trial thus triggering the following milestone: $1 million cash + 2 million shares of Pharmos common stock: Final patient enrolled in Phase 2b trial. The expense of the milestone of $1,180,000 has been reflected in the first quarter 2009 results. The payment of the cash portion of the milestone has been deferred under an amendment to the acquisition agreement. Under the terms of the Vela acquisition agreement as amended, the 2 million shares will be issued on November 2, 2009.

General and administrative expenses for the first half of 2009 decreased by $491,444, or 39%, from $1,250,989 in 2008 to $759,545 in 2009. The decline reflects decreases in virtually every general and administrative exp
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Pharmos Completes Private Placement - Raises $1.8 Million
8. Pharmos Corporation Reports 2009 First Quarter Results
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CREEK, Calif., March 4 Longs Drug,Stores Corporation (NYSE: ... a quarterly cash dividend on common shares of $0.14 per ... the close of,business on March 11, 2008., About the ... (NYSE: LDG ) is one of the most recognized ...
... produced another article [1], which probably marks the opening ... of a further 2.4-year follow-up (after cessation of the ... P) cohort are reported. They concluded that, by the ... newly formed and unvalidated tool used in the WHI ...
... - Second Phase III clinical trial to begin ... 4 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... it has received notice from,the U.S. Food and ... bladder cancer meets the criteria for Fast Track,designation. ...
... continued need for mammograms , , TUESDAY, March 4 (HealthDay News) ... woman stops taking combination hormone replacement therapy, a new study ... issue of the Journal of the American Medical Association ... Initiative (WHI). That trial was halted abruptly in 2002, when ...
... G.,Rendell,s health care team today told a state ... Pennsylvanians continues to grow and, with the,addition of ... there are,funds to pay for providing the uninsured ... the House of Representatives Appropriations,Committee that continuing the ...
... annual KID,HEALTHY--Steps to Healthy Living Campaign, SANTA ... trend of childhood obesity in Southern California schools, ... parents from Los Angeles,Orange, Riverside, San Bernardino, San ... participate in the KID HEALTHY--Steps to Healthy,Living Campaign. ...
Cached Medicine News:Health News:Health risks after cessation of postmenopausal hormone therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 3Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 2Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 4Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... BerGenBio AS, a biopharmaceutical company ... cancers, today announces that it has raised NOK90 million ... and existing investors. BerGenBio will use the ... its pipeline of innovative cancer therapeutics, in particular an ... BGB324, a first-in-class selective Axl kinase inhibitor, which is ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... , THOUSAND OAKS, Calif., Sept. 21 ... from a Phase 3 trial evaluating denosumab administered subcutaneously versus ... treatment of bone metastases in 1,776 advanced cancer patients with ... myeloma. These results were presented today at the 2009 ...
... MADISON, Conn., Sept 18 Further results from the initial clinical ... treatment for varicose veins, will be delivered on Friday, September 25, ... Philadelphia. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 2Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 3Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 5Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 6Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 7Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 8Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 9ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2
... An external computer-enhanced microplate reader ... provides automated flexible and rapid ... for accurate and reliable photometric ... or without shaking before reading) ...
... a number of assay steps for ... simple to use benchtop device. The ... stand-alone device but also provides easy ... and standard add-on modules provide maximum ...
... AP-22 Micro Plate Processor is ... Automated Microplate Analyzer. It has been ... assigned area can be customised according ... Micro Plate Processor is able to ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Medicine Products: